8-K: Centene Corporation Reports Solid 2023 Results, Exceeds EPS Guidance and Increases 2024 Revenue Outlook

Centene Corporation announced its 2023 financial results, exceeding adjusted EPS guidance and increasing its 2024 premium and service revenue guidance by $2.5 billion.

Summary

• Centene Corporation reported its financial results for the fourth quarter and full year of 2023.
• The company's full-year diluted EPS was $4.95, and adjusted diluted EPS reached $6.68, a 15% increase from 2022.
• Full year premium and service revenues totaled $140.1 billion, a 3% increase year-over-year.
• The health benefits ratio for the full year was 87.7%, consistent with the previous year.
• Centene executed $1.6 billion in share repurchases during 2023.
• The company completed the divestitures of Circle Health and Operose Health.
• Centene increased its 2024 premium and service revenues guidance by $2.5 billion.
• Total revenues for 2023 reached $153.999 billion.
• Cash flow provided by operations for the full year was $8.1 billion.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, exceeding EPS guidance, and increased revenue guidance. The strategic divestitures and share repurchases also contribute to a positive sentiment. However, the decrease in Medicare membership and the increase in the health benefits ratio in Q4 are minor concerns.

Positives

• Centene's adjusted diluted EPS exceeded previous guidance, indicating strong financial performance.
• The company's health benefits ratio remained stable year-over-year, demonstrating effective cost management.
• The completion of international divestitures simplifies the business and allows for greater focus on core operations.
• The increase in 2024 revenue guidance suggests positive future growth prospects.
• The company's share repurchase program demonstrates confidence in its financial position and commitment to shareholder value.
• The commercial marketplace business experienced significant membership growth.
• Centene was named to Fortune's list of World's Most Admired Companies for the sixth consecutive year.

Negatives

• The company's Medicare membership decreased year-over-year.
• The health benefits ratio increased in Q4 2023 to 89.5% from 88.7% in Q4 2022, primarily due to a $250 million premium deficiency reserve related to the 2024 Medicare Advantage business.
• The SG&A expense ratio increased in both Q4 and full year 2023, driven by growth in the Marketplace business and Medicare distribution costs.
• Medicaid membership decreased from 15,974,800 in 2022 to 14,472,000 in 2023.

Risks

• The company faces risks related to managing health benefits and operating expenses, including fluctuations in medical utilization rates.
• Competition in the healthcare industry could impact the company's ability to maintain or grow its market share.
• Changes in government regulations and healthcare policies could affect the company's revenue and profitability.
• The company is subject to risks related to legal and regulatory audits and investigations.
• The company's ability to maintain or improve CMS Star ratings could impact revenue and future growth.
• The company faces risks related to cyber-attacks and data security incidents.

Future Outlook

Centene increased its 2024 premium and service revenues guidance range by $2.5 billion to a range of $134.5 billion to $137.5 billion and reiterated its 2024 adjusted diluted EPS guidance floor of greater than $6.70.

Management Comments

• Our fourth quarter and full year 2023 adjusted EPS results are slightly ahead of previous guidance, providing our organization with tangible, positive momentum as we enter 2024.
• Looking ahead, we are excited by the opportunities we see within our core businesses as we execute against our strategic plan, fortify our foundational assets and drive cost savings.
• With increased focus and reduced complexity, Centene is well positioned to continue navigating the dynamic operating landscape while creating shareholder value.

Industry Context

The healthcare industry is experiencing significant changes, including shifts in government programs and increased competition. Centene's results reflect its ability to adapt to these changes, particularly in the growth of its Marketplace business and the strategic divestiture of international operations. The company's focus on core businesses and cost savings aligns with industry trends towards efficiency and profitability.

Comparison to Industry Standards

• Centene's adjusted diluted EPS growth of over 15% year-over-year is a strong performance compared to many of its peers in the managed healthcare sector.
• Competitors such as UnitedHealth Group and Humana have also reported strong results, but Centene's growth in the Marketplace segment is particularly noteworthy.
• The health benefits ratio of 87.7% is within the typical range for managed care companies, but the increase in Q4 due to the Medicare Advantage reserve is a point of concern.
• The company's share repurchase program is a common practice among large healthcare companies to return value to shareholders.
• The divestiture of international assets is a strategic move that aligns with the trend of companies focusing on core domestic markets.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the strong financial results, share repurchases, and increased revenue guidance.
• Employees may experience changes due to restructuring and management changes.
• Customers will continue to receive healthcare services through Centene's various programs.
• Providers will continue to partner with Centene to deliver healthcare services.
• Government partners will continue to work with Centene on government-sponsored healthcare programs.

Next Steps

• Centene will continue to execute its strategic plan, focusing on core businesses and cost savings.
• The company will continue to monitor and manage its health benefits ratio and SG&A expenses.
• Centene will work to integrate new contracts and manage the transition of divested businesses.
• The company will host a conference call on February 6, 2024, to discuss the financial results.

Key Dates

Keywords

Centene, Healthcare, Financial Results, EPS, Revenue, Medicaid, Medicare, Health Benefits Ratio, Share Repurchase, Divestiture, Marketplace, Membership